Skip to content
Search

Latest Stories

NHS England cracks deal for cystic fibrosis triple

NHS England said on Tuesday (June 30) that it has agreed a deal with Vertex Pharmaceuticals for its three-drug cystic fibrosis therapy Kaftrio.

The agreement allows Cystic Fibrosis (CF) patients in England to access Kaftrio when the European Medicines Agency (EMA) grants formal approval to the drug, said NHS England chief executive Sir Simon Stevens.


“The new expanded agreement includes reimbursed access to Vertex’s currently licensed medicines- Kalydeco (ivacaftor), Orkambi  (lumacaftor/ivacaftor), and Symkevi  (tezacaftor/ivacaftor), as well as the triple combination therapy if approved - and any future additional licensed indications for all of these medicines,” Vertex Pharmaceuticals said in a statement.

With the latest move, England will be the first country to access the drug in Europe. As many as 7,000 people, including 300 with rare mutations, which fall outside of the scope of EMA approvals.

Health Secretary Matt Hancock tweeted: “So delighted we have struck a deal with Vertex on Trikafta (to be called Kaftrio over here) - the next generation Cystic Fibrosis drug.

“This deal will save lives. Huge congratulations to the NHS team who landed the deal”.

CF community has welcomed the new deal as it had concerned that a prolonged negotiation over pricing could delay the drug’s availability in the UK.

As part of the agreement with NHS England, Vertex has agreed to submit Orkambi, Symkevi, and Kaftrio to the National Institute for Health and Care Excellence (NICE), allowing for a period of real-world data collection on the medicines.

Vertex will be working closely with the authorities in Northern Ireland, Wales and Scotland with the aim of securing an equivalent agreement in those countries as soon as possible.

Reshma Kewalramani, CEO and president at Vertex, said, “NHS England has recognized the value of Kaftrio, and that Vertex and NHS England have been able to work quickly, collaboratively and flexibly to expand the existing reimbursement agreement to include the triple combination therapy in advance of the medicine being licenced. This will ensure that eligible patients in England will be among the first in Europe to benefit from access to this innovative medicine upon approval.”

The EMA's Committee for Medicinal Products for Human Use (CHMP) has recently adopted a positive opinion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with Kalydeco (ivacaftor) 150 mg to treat people with cystic fibrosis (CF) ages 12 and older with one F508del mutation and one minimal function mutation or two F508del mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Vertex’s CF medicines are reimbursed in more than 20 countries around the world including Australia, France, Germany, the Republic of Ireland, Italy, Switzerland, Spain, Denmark, the UK and the US.

More For You

Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Asda pharmacy launches UK’s first adult earache service

Asda makes ear health more accessible for everyone

gettyimages

Asda pharmacy launches £25 adult earache service

British supermarket chain Asda has launched the “UK’s first” adult earache service, aiming to reduce the burden on NHS services by eliminating the need for a GP appointment.

Priced at £25, the service allows patients aged 18 and over to book same-day appointments with qualified Asda pharmacists at any of its 226 pharmacies in England.

Keep ReadingShow less
Dr Penelope Dash new chair of NHS England

Dr Penny Dash is currently the chair of the NHS North West London Integrated Care Board

parliamentlive

Dr Penelope Dash appointed as new chair of NHS England

Dr Penny Dash has been appointed as the next chair of NHS England following an open public appointment process.

She will succeed Richard Meddings, who is set to step down next month, and her four-year term begins on April 1, 2025.

Keep ReadingShow less
Nearly two-thirds of people think the NHS should be prioritised to receive more public spending in the future

Nearly two-thirds of people think the NHS should be prioritised to receive more public spending in the future

gettyimages

Over 70% public unaware of NHS 10-Year Health Plan – poll finds

Despite widespread promotion, nearly three-quarters (73%) of the English public remain unaware of the government’s 10-Year Health Plan for the NHS, according to new polling by the Health Foundation and Ipsos.

Once informed about the plan, just over a third (35%) expressed confidence that it would lead to improvements in the health service, while 59% remained unconvinced.

Keep ReadingShow less
Hospices receive £25 million for facility upgrades and refurbishments

The finding will help reform the palliative and end of life care system

gettyimages

Hospices receive £25 million for facility upgrades and refurbishments


The government has confirmed the release of £25 million for upgrades and refurbishments for hospices across England, as part of the biggest investment into hospices in a generation.

Keep ReadingShow less